Influencing factors and the clinical significance of tumorigenesis rate in PDX model of colorectal cancer

doi:10.16352/j.issn.1001-6325.2023.04.0596

Abstract

Abstract: Objective To establish a patient derived xenograft (PDX) model of tumor tissue from patients with colorectal cancer (CRC) and to identify the factors affecting the tumorigenesis rate of PDX model, as well as to conduct a preliminary chemotherapy. Methods From November 2019 to October 2020, CRC patients undergoing elective surgery in Shaoxing People's Hospital were selected. The tumor tissue obtained from surgical operation was inoculated to the right lumbar back of NSG mice to establish a PDX model, which was subcultured to F3 generation, and the influencing factors of the tumor formation rate of PDX model were analyzed. Chemotherapy drugs include 5-fluorouracil, oxaliplatin and anesthetic propofol. Results A total of 60 patients with CRC were included in this study and 37 samples from patients had PDX tumor formation in mice with a tumorigenesis rate of 62%; The average tumorigenesis time was (34±12)d; Primary tumor malignant degree (tumor stage and degree of cell differentiation), preoperative carcinoembryonic antigen (CEA) level and tumor location of CRC patients affected the tumorigenesis rate of PDX model (P＜0.01). The biology of CRC-PDX transplanted tumor tissue was highly consistent with that of the patient's tumor tissue. All four chemotherapy regimens could inhibit tumor growth and cause tumor tissue damage. Propofol could inhibit diarrhea in mice and protect intestinal mucosa. Conclusions The CRC-PDX model established in this study may better keep biological characteristics of primary tumors and be used as a reference model for individualized treatment of CRC patients. The malignant degree of the primary tumor is the main factor affecting the tumorigenesis rate of PDX model.

Key words: colorectal cancer, patient derived xenograft, influencing factors, tumorigenesis rate, individualized treatment

CLC Number:

ZHANG Yanping, YAO Liuxu, DING Qiannan, HUANG Zeyong, LI Yuhong, HUANG Suqin. Influencing factors and the clinical significance of tumorigenesis rate in PDX model of colorectal cancer[J]. Basic & Clinical Medicine, 2023, 43(4): 596-602.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal11.magtechjournal.com/Jwk_jcyxylc/EN/10.16352/j.issn.1001-6325.2023.04.0596

http://journal11.magtechjournal.com/Jwk_jcyxylc/EN/Y2023/V43/I4/596

References

[1]Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022[J]. CA Cancer J Clin, 2022,72:7-33.
[2]Wang W, Kandimalla R, Huang H, et al. Molecular subtyping of colorectal cancer: recent progress, new challen-ges and emerging opportunities[J]. Semin Cancer Biol, 2019, 55:37-52.
[3]Rizzo G, Bertotti A, Leto SM, et al. Patient-derived tumor models: a more suitable tool for pre-clinical studies in colorectal cancer[J]. J Exp Clin Cancer Res, 2021,40:178. doi: 10.1186/s13046-021-01970-2.
[4]Voulgarelis D, Bulusu KC, Yates JWT. Comparison of classical tumour growth models for patient derived and cell-line derived xenografts using the nonlinear mixed-effects framework[J]. J Biol Dyn, 2022,16:160-185.
[5]Costa B, Estrada MF, Barroso MT, et al. Patient-derived avatars from digestive cancers for anti-cancer therapy screening[J]. Curr Protoc, 2022, 2:e415. doi: 10.1002/cpz1.415.
[6]Guo S, Gao S, Liu R, et al. Oncological and genetic factors impacting PDX model construction with NSG mice in pancreatic cancer[J]. FASEB J, 2019,33:873-884.
[7]Abdolahi S, Ghazvinian Z, Muhammadnejad S, et al. Patient-derived xenograft (PDX) models, applications and challenges in cancer research[J]. J Transl Med, 2022,20:206.doi: 10.1186/s12967-022-03405-8.
[8]Ji X, Chen S, Guo Y, et al. Establishment and evaluation of four different types of patient-derived xenograft models[J]. Cancer Cell Int, 2017,17:122.doi: 10.1186/s12935-017-0497-4.
[9]Huang L, Wang J, Fang B, et al. CombPDX: a unified statistical framework for evaluating drug synergism in patient-derived xenografts[J]. Sci Rep, 2022,12:12984.doi: 10.1038/s41598-022-16933-6.
[10]Zhang H, Yuan L, Liu L, et al. Dynamic alterations of genome and transcriptome in KRAS G13D mutant CRC PDX model treated with cetuximab[J]. BMC Cancer, 2020,20:416.doi: 10.1186/s12885-020-06909-y.
[11]Cheng Y, Qin SK, Li J, et al. A multicenter clinical study: personalized medication for advanced gastrointes-tinal carcinomas with the guidance of patient-derived tumor xenograft (PDTX)[J]. J Cancer Res Clin Oncol, 2022,148:673-684.
[12]Lee S, Pyo DH, Sim WS, et al. Early and long-term outcomes after propofol-and sevoflurane-based anesthesia in colorectal cancer surgery: A retrospective study[J]. J Clin Med, 2022,11:2648.doi: 10.3390/jcm11092648.
[13]Kang FC, Wang SC, So EC, et al. Propofol may increase caspase and MAPK pathways, and suppress the Akt pathway to induce apoptosis in MA 10 mouse Leydig tumor cells[J]. Oncol Rep, 2019,41:3565-3574.
[14]Zhang Y, Ding X, Miao C, et al. Propofol attenuated TNF-α-modulated occludin expression by inhibiting Hif-1α/VEGF/VEGFR-2/ERK signaling pathway in hCMEC/D3 cells[J]. BMC Anesthesiol, 2019,19:127.doi: 10.1186/s12871-019-0788-5.
[15]王玉龙, 滕文彬, 单跃, 等. HIF-1α激动或拮抗剂对脓毒症大鼠肠道黏膜通透性的影响[J]. 基础医学与临床, 2021, 41: 1618-1623.